Vibecotamab治疗复发/难治性急性髓系白血病的1期研究确定优化剂量
这项1期研究评估了CD3/CD123双特异性抗体vibecotamab单药治疗复发/难治性急性髓系白血病的安全性和耐受性,并确定最大耐受剂量/推荐剂量。采用3次递增剂量(第1周)后每周给药方案可减少细胞因子释放综合征。120例中16例至少1起治疗中出现的不良事件被归类为剂量限制性毒性,细胞因子释放综合征最常见(59.2%),大多≤2级。111例可评估疗效的AML患者中10例(9.0%)达到形态学无白血病状态或更好,总客观缓解率为9.0%;仅在目标剂量≥0.75 μg/kg的患者(n=87)中观察到缓解,该组可评估疗效的客观缓解率为11.5%。
要点
- 3次递增剂量(第1周)后每周给药方案可减少细胞因子释放综合征。
- 细胞因子释放综合征最常见(59.2%),经预给药管理后大多≤2级。
- 目标剂量≥0.75 μg/kg组可评估疗效的客观缓解率为11.5%,总客观缓解率为9.0%。
核心结论
- Vibecotamab单药治疗复发/难治性AML的推荐2期剂量方案为第1周3次递增剂量后每周给药(1.7 μg/kg,队列-1D)。
- 缓解仅在目标剂量≥0.75 μg/kg的患者中观察到,且与血液和骨髓中较低的基线原始细胞计数(<25%)相关,提示潜在获益。
研究设计与样本
- 1期研究,主要目标为安全性和耐受性以及确定单药治疗复发/难治性AML的最大耐受剂量/推荐剂量。
- 共120例患者纳入安全性分析,111例AML患者可评估疗效。
- 试验注册号NCT02730312。
主要发现
- 120例中16例至少1起治疗中出现的不良事件被归类为剂量限制性毒性。
- 细胞因子释放综合征为最常见不良事件(59.2%),经预给药管理后大多≤2级。
- 111例可评估疗效的AML患者中10例(9.0%)达到形态学无白血病状态或更好,总客观缓解率为9.0%。
- 目标剂量≥0.75 μg/kg的患者(n=87)中可评估疗效的客观缓解率为11.5%。
- 缓解与血液和骨髓中较低的基线原始细胞计数(<25%)相关。
关键数值与推荐
- 推荐2期剂量方案:第1周3次递增剂量后每周给药(1.7 μg/kg,队列-1D)。
- 目标剂量≥0.75 μg/kg(n=87)可评估疗效的客观缓解率为11.5%。
- 总客观缓解率为9.0%(10/111)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML), an aggressive malignancy with unmet medical need, lacks immunotherapeutic options. CD123, the cellular receptor for interleukin-3, expressed in AML is an attractive target for tumor-specific therapy. Vibecotamab (XmAb14045), a humanized bispecific antibody, monovalently binds both CD3 and CD123 to recruit cytotoxic T cells to kill CD123+ tumor cells. This phase 1 study's primary objectives were safety and tolerability and identification of a maximum tolerated dose/recommended dose for use as monotherapy in patients with relapsed/refractory AML. Identification of a recommended phase 2 vibecotamab dose comprised 3 step-up doses (Week 1), which were noted to reduce cytokine response syndrome (CRS), followed by weekly dosing (1.7 μg/kg, Cohort -1D). In 16 of 120 patients, at least 1 treatment-emergent adverse event was classified as a dose-limiting toxicity. CRS, the most common adverse event (59.2%), managed with premedication, were mostly ≤grade 2. A secondary objective was assessment of efficacy in patients with CD123-expressing leukemias. A total of 10 of 111 (9.0%) efficacy-evaluable patients with AML achieved an overall response of morphologic leukemia-free state or better with an overall objective response rate (ORR) of 9.0%. Response was only observed in patients receiving a target dose of 0.75 μg/kg or higher (n = 87) in which the efficacy-evaluable ORR was 11.5%. Response was associated with lower baseline blast counts in blood and bone marrow (<25%) suggesting potential benefit. This trial was registered at www.clinicaltrials.gov as #NCT02730312.
引用
- Ravandi F, Bashey A, Foran J, et al. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023. PMID: 37647601. doi:10.1182/bloodadvances.2023010956
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。